Earnings call transcript: Sandoz sees stock surge in Q1 2026

Sandoz posted Q1 net sales of $2.8 billion, up 11% reported and 3% constant currency, with biosimilar sales rising 18% and now representing 31% of total sales. Management reaffirmed FY2026 guidance for mid-to-high single-digit constant-currency sales growth and about 100 bps of core EBITDA margin expansion, while noting a 4 percentage point FX tailwind for the year. The stock rose 19.19% after the earnings call as investors focused on strong biosimilar momentum, launch execution, and the Samsung partnership.

Analysis

The market is re-rating Sandoz not just on the quarter, but on the credibility of its launch engine. The important second-order effect is that biosimilar mix improvement can compound even if gross price pressure persists, because the company is increasingly winning through channel access, early formulary placement, and geographic rollout breadth rather than pure price. That makes the moat more operational than scientific: scale in regulatory, market access, and manufacturing is now the key barrier to entry, which should disadvantage smaller biosimilar players that lack multi-country execution or vertical integration.

The clearest winners are the contract-development/manufacturing ecosystem and upstream partners that can absorb more asset-light pipelines. Samsung’s role signals that Sandoz is willing to trade some economics for speed and pipeline breadth, which lowers capital intensity but also raises dependence on third-party execution quality. For competitors, especially smaller biosimilar specialists, the message is bearish: the market is consolidating around a few scaled platforms, and the winners will be those with broad portfolios that can monetize one launch while funding the next.

The main risk is not near-term demand, but valuation and expectations. The company is effectively pulling forward the market’s confidence in a 2027-28 growth bridge before the next wave of LOEs fully hits, so any stumble in U.S. adoption, pricing discipline, or manufacturing readiness would hit the multiple harder than the earnings line. The key catalyst window is the next two quarters: if Q2 and Q3 show the promised washout of generics drag plus continued biosimilar share gains, the stock can rerate further; if not, the recent move likely compresses into a sell-the-news setup.

Contrarian view: the market may be underestimating how much of this story is actually about pricing discipline, not just volume. Management’s emphasis on value share over volume share in denosumab suggests they are already thinking beyond peak-share optics, which is bullish for margin stability but implies slower headline uptake than bulls may expect. That makes the path to upside more gradual, but also more durable if they execute.

Key Decisions for Investors

• Go long Sandoz via equity or call spreads on a 3-6 month horizon; use pullbacks after launch-driven strength, with upside tied to confirmation that Q2/Q3 biosimilar growth offsets generics drag.
• Pair trade: long Sandoz / short a smaller biosimilar pure-play or generic-heavy peer for 3-6 months; thesis is that scale, access, and multi-launch execution will separate winners as the biosimilar cycle matures.
• Buy downside protection on the high-expectation leg into the next earnings/launch print: consider Sandoz put spreads or collars if the stock extends further before Q2 results, since the move is vulnerable to any launch slippage.
• Overweight contract development/manufacturing beneficiaries with biosimilar exposure over generic API suppliers for 6-12 months; the market is shifting toward integrated launch platforms rather than commodity supply.